Vir Biotechnology, Inc. Form 8-K (May 21, 2021)

Summary

Form 8-K current report of Vir Biotechnology, Inc. dated May 21, 2021, filed under Item 8.01 (Other Events). It reports that on May 21, 2021 the company and GlaxoSmithKline plc issued a corrected press release announcing that the European Medicines Agency's Committee for Human Medicinal Products (CHMP) issued a positive opinion following the referral of sotrovimab under Article 5(3) of Regulation 726/2004. The corrected press release is attached as Exhibit 99.1 and incorporated by reference. The report is signed by Howard Horn.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 21, 2021

Vir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-39083 | 81-2730369
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)

499 Illinois Street , Suite 500

San Francisco , California 94158

(Address of principal executive offices, including zip code)

(415) 906-4324

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.0001 par value per share | VIR | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 | Other Events.

On May 21, 2021, Vir Biotechnology, Inc. (the “Company”) and GlaxoSmithKline plc (“GSK”) issued a corrected press release announcing that the European Medicines Agency’s Committee for Human Medicinal Products (“CHMP”) has issued a positive opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. A copy of the corrected press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 | Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. | Description
99.1 | Corrected Press Release of the Company, dated May 21, 2021.
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIR BIOTECHNOLOGY, INC.
Date: May 21, 2021 | By: | /s/ Howard Horn
Howard Horn
Chief Financial Officer

File and source

File

SEC_VIR_8-K_filed2021-05-21_0001193125-21-169206.htm

Size

25,138 bytes

SHA-256

e3596846256bec4e119c6f4094ea21b9c1f0e197937e6da5d28ac93c6663a127

Our copy

SEC_VIR_8-K_filed2021-05-21_0001193125-21-169206.htm

Original

www.sec.gov

Exhibits

Exhibit 99.1: Vir Biotechnology, Inc., "CORRECTION: EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology's Sotrovimab For the Early Treatment of COVID-19"